BIOPHARMA
ByIs Takeda’s $1.7B Bet on Iambic Therapeutics the Defining Moment for AI-Validated Drug Discovery?
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…
Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Innovent and Eli Lilly Expand Strategic Alliance to Advance Immunology and Oncology Innovation
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion to Advance In Vivo Cell Therapy Platform
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution or Urban Elite Tool?
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
